Efficacy News and Research

RSS

Triple drug regimen proven effective against non-structural protein-1 of SARS-CoV-2

Researchers evaluated the synergistic activity of drugs acting against non-structural protein 1 of SARS-CoV-2 to decrease the viral infectivity.

2 Mar 2022

Dual therapeutic potential of zapnometinib against COVID-19

Researchers assessed the impact of the drug zapnometinib on human immune response against coronavirus disease 2019.

2 Mar 2022

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

A new study describes the efficacy of adenosine receptor agonists in the treatment of SARS-CoV-2 infection.

2 Mar 2022

Antigenic differences between Omicron BA.1 and BA.2 SARS-CoV-2 variants

A new study identifies the antigenic differences that exist between the Omicron BA.2 and BA.1 variants.

2 Mar 2022

Study reports substantial loss of protection one month after complete SARS-CoV-2 BNT162b2 immunization in children

A new study evaluated the efficacy of Pfizer’s BNT162b2 vaccine in children aged 17 years or younger after the emergence of the SARS-CoV-2 Omicron variant.

2 Mar 2022

Population-level health and economic impact of the Pfizer-BioNTech COVID-19 vaccine in first year of rollout in the US

A new study shows the impact of the vaccine program on the state of public health in the USA.

2 Mar 2022

Targeting necroptosis using a necroptosis inhibitor lessens myositis-induced muscle weakness

A new study has suggested that treatment to target necroptosis in muscle fibers using a necroptosis inhibitor lessens myositis-induced muscle weakness as well as muscle cell death and inflammation in the muscles. This has been shown to be a promising strategy for treating polymyositis.

2 Mar 2022

Masks made of woven fabrics are lousy air filters

Like many other viruses, COVID-19 is transmitted primarily via particles carried in the air. An infected person breathes out particles containing the virus into the air, which can then be inhaled by another person, who then becomes infected.

1 Mar 2022

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

1 Mar 2022

Researchers launch a multi-center trial to investigate new treatment for pediatric type 1 diabetes

Researchers at Massachusetts General Hospital, in partnership with NYU Langone Health, have launched a multi-center clinical trial to investigate a new treatment for pediatric type 1 diabetes even in subjects with established disease.

1 Mar 2022

Intensive treatment for patients with Crohn's disease found to be safe

Intensive treatment for patients with Crohn's disease showed no safety differences compared to the current standard of care, according to a trial published in the journal Gastroenterology.

1 Mar 2022

Impact of COVID-19 boosters on protection against SARS-CoV-2 infection in a highly vaccinated population

A recent study analyzed the impact of COVID-19 booster vaccines against the SARS-CoV-2 Omicron VOC in a vaccinated population.

1 Mar 2022

Association between booster breakthrough infections with the SARS-CoV-2 Omicron variant and time-since-vaccination

A recent study assessed the waning efficacy of the BioNTech/Pfizer BNT162b2 mRNA vaccine against the SARS-CoV-2 Omicron VOC.

1 Mar 2022

Effectiveness of Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines in preventing severe SARS-CoV-2 infection

A new study compared the effectiveness of the Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines in preventing SARS-CoV-2 infections.

1 Mar 2022

J&J-vaxxed, mRNA-boosted, and pondering a third shot

Yes, we are all exhausted by the covid pandemic. Flummoxed by the constantly shifting science and guidelines. Worried about a succession of scary new variants, each with its own name, like hurricanes.

1 Mar 2022

Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model

Researchers found that an antiviral drug, was effective against SARS-CoV-2 variants, including the recently emerged Omicron variant, in Syrian hamsters.

1 Mar 2022

Recombinant adenovirus vector vaccine generates mucosal antibodies against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of three candidate vaccines, ED88, ED90, and ED94, to select the most appropriate one for future development.

1 Mar 2022

First platform trial for ALS hopes to accelerate the development of effective treatments

A new paper in Annals of Neurology describes the approach, structure, and launch of the HEALEY ALS Platform Trial– the first platform trial for amyotrophic lateral sclerosis (ALS) designed to accelerate the development of effective and breakthrough treatments for people with the illness.

28 Feb 2022

Breakthrough SARS-CoV-2 infection peaks at 5 months

A new study describes the incidence of breakthrough infection with SARS-CoV-2 after vaccination with one of the nucleic acid or viral vector vaccines.

28 Feb 2022

Researchers report a new, more efficient way to grow breast cancer models

For years, researchers at Huntsman Cancer Institute at the University of Utah have honed a process of developing breast cancer models using tumors donated by breast cancer patients, which they then implant into mice as a way to study the tumor's behavior.

28 Feb 2022

Efficacy News and Research

Triple drug regimen proven effective against non-structural protein-1 of SARS-CoV-2

Dual therapeutic potential of zapnometinib against COVID-19

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

Antigenic differences between Omicron BA.1 and BA.2 SARS-CoV-2 variants

Study reports substantial loss of protection one month after complete SARS-CoV-2 BNT162b2 immunization in children

Population-level health and economic impact of the Pfizer-BioNTech COVID-19 vaccine in first year of rollout in the US

Targeting necroptosis using a necroptosis inhibitor lessens myositis-induced muscle weakness

Masks made of woven fabrics are lousy air filters

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

Researchers launch a multi-center trial to investigate new treatment for pediatric type 1 diabetes

Intensive treatment for patients with Crohn's disease found to be safe

Impact of COVID-19 boosters on protection against SARS-CoV-2 infection in a highly vaccinated population

Association between booster breakthrough infections with the SARS-CoV-2 Omicron variant and time-since-vaccination

Effectiveness of Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines in preventing severe SARS-CoV-2 infection

J&J-vaxxed, mRNA-boosted, and pondering a third shot

Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model

Recombinant adenovirus vector vaccine generates mucosal antibodies against SARS-CoV-2

First platform trial for ALS hopes to accelerate the development of effective treatments

Breakthrough SARS-CoV-2 infection peaks at 5 months

Researchers report a new, more efficient way to grow breast cancer models

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News